Early Positive Outcomes in Phase 1 Deltacel-01 Trial Show Tumor Shrinkage

A recent clinical study by Kiromic BioPharma, Inc. has shown positive results in the treatment of stage 4 metastatic non-small cell lung cancer (NSCLC) with their drug candidate, Deltacel™. The first patient in the Phase 1 Deltacel-01 trial exhibited a 6.6% reduction in tumor size and a 20% decrease in tumor metabolism two months after treatment, with no new metastasis detected. The patient, treated at Beverly Hills Cancer Center (BHCC), is reported to be in good health following the treatment.
Kiromic's CEO, Pietro Bersani, expressed optimism about the early outcomes, highlighting the lack of treatment options for this patient group. The company also announced that the second patient in the trial has completed the final dose of Deltacel and is expected to provide initial data on tolerability and safety in March, with preliminary efficacy results by the end of the first quarter. The third patient has been dosed and is anticipated to finish treatment soon, with further patient enrollment planned for additional clinical trial sites later in the year.
The Deltacel-01 trial combines Gamma Delta T-cell infusions with low-dose radiotherapy to assess the safety and effectiveness of this approach for NSCLC patients. Deltacel, an allogeneic product derived from donor gamma delta T cells, targets solid cancers and is being tested for its safety, response rates, and survival outcomes in the current study.
Kiromic BioPharma is a clinical-stage biotherapeutics company that utilizes its DIAMOND® AI 2.0 technology for the development of cell therapies, specifically focusing on immuno-oncology. They are developing a platform for allogeneic cell therapies to target solid tumors, leveraging the power of Gamma Delta T-cells. The Beverly Hills Cancer Center is a private, academic, community-based facility offering advanced cancer treatments and clinical trials, attracting patients worldwide.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!